製品番号: HY-N7400

Phaseoloidin

カスタマーレビュー

Based on 1 Customer Validation

Phaseoloidin is an orally active multi-target inhibitor. Phaseoloidin inhibits the activation of the NLRP3 inflammasome and blocks the caspase-11-GSDMD pyroptosis axis. Phaseoloidin reduces the expression of collagen-degrading enzymes to maintain the integrity of cartilage matrix. Phaseoloidin activates the AMPK/mTOR pathway to enhance autophagy function and reverse apoptosis resistance. Phaseoloidin inhibits the growth and development of Manduca sexta and Spodoptera littoralis larvae, thereby helping Nicotiana attenuata defend against lepidopteran herbivorous insects. Phaseoloidin can be used in research related to acute gouty arthritis and pulmonary fibrosis.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.92%
CAS 番号: 118555-82-1
分子式: C₁₄H₁₈O₉
分子量:330.29

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Phaseoloidin 構造式

CAS 番号: 118555-82-1

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

NOD-like Receptor (NLR) アイソフォーム固有の製品をすべて表示 :

Caspase アイソフォーム固有の製品をすべて表示 :

AMPK アイソフォーム固有の製品をすべて表示 :

mTOR アイソフォーム固有の製品をすべて表示 :

体外実験

Phaseoloidin (6.25-200 μM; 24 h) is non-cytotoxic to mouse peritoneal macrophages at concentrations up to 200 μM following 24 h incubation^[1].
Phaseoloidin (6.25-200 μM; 24 h) is non-cytotoxic to rat articular chondrocytes at concentrations up to 100 μM following 24 h incubation, with only mild cytotoxicity at 200 μM^[1].
Phaseoloidin (25-100 μM; 1 h pre-incubation, followed by 22 h total incubation with LPS and sodium urate crystals) dose-dependently inhibits NLRP3 inflammasome activation and downstream inflammatory mediator release in LPS/sodium urate-stimulated mouse peritoneal macrophages, with maximal effects at 100 μM^[1].
Phaseoloidin (10-100 μM; 48 h) activates the AMPK/mTOR pathway to promote autophagy in TGF-β1-induced primary mouse lung myofibroblasts^[2].
Phaseoloidin (3-300 μM) does not reduce the viability of TGF-β1-induced primary mouse lung myofibroblasts^[2].
Phaseoloidin (10-100 μM; 48 h) promotes autophagy-mediated collagen degradation in TGF-β1-induced primary mouse lung myofibroblasts via the AMPK pathway^[2].
Phaseoloidin (10-100 μM; 48 h co-treatment with FasL) reverses FasL-induced apoptosis resistance in TGF-β1-induced primary mouse lung myofibroblasts via the AMPK pathway^[2].
Phaseoloidin (10-100 μM; 48 h co-treatment with FasL) promotes autophagy-mediated degradation of PTPN13 to restore FasL-induced apoptosis sensitivity in TGF-β1-induced primary mouse lung myofibroblasts^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Rat articular chondrocytes
Concentration:

6.25-200 μM
Incubation Time:

24 h
Result:

Showed no significant cytotoxicity at concentrations ≤100 μM relative to untreated cells.
Caused a minor but significant reduction in viability at 200 μM relative to untreated cells.

体内実験

Phaseoloidin (25-100 mg/kg; i.g.; single dose 1 hour pre-challenge) dose-dependently ameliorates sodium urate-induced acute gouty arthritis in mice by inhibiting NLRP3 inflammasome activation, caspase-11-GSDMD-mediated pyroptosis, NETosis, and cartilage matrix degradation^[1].
Phaseoloidin (25-100 mg/kg; i.g.; single dose 1 hour pre-challenge) dose-dependently suppresses sodium urate-induced acute gout inflammation in mouse air pouches by inhibiting NLRP3 inflammasome activation, pyroptosis, and NETosis, with high-dose treatment normalizing lavage fluid IL-1β levels^[1].
Phaseoloidin (1-25 mg/kg; i.p.; daily; days 14-28) exerts dose-dependent antifibrotic effects in Bleomycin (HY-108345)-induced pulmonary fibrosis in male C57/BL mice via AMPK-mediated autophagy activation^[2].
Phaseoloidin (0.16 μg/mg of diet; oral; continuous feeding; 12 days) reduces Manduca sexta larval growth by 50%^[3].
Phaseoloidin (0.16 μg/mg of diet; oral; continuous feeding; 8 days) reduces Spodoptera littoralis larval growth by 55%^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Kunming mice (male, 6-8 weeks old, acute gouty arthritis induced by sodium urate crystal paw injection)^[1]
Dosage:

25-100 mg/kg
Administration:

i.g.; single dose 1 hour pre-challenge
Result:

Attenuated paw swelling dose-dependently at 1 hour post-sodium urate injection.
Reduced paw erythema and swelling.
Decreased immune cell infiltration in articular cavity and periarticular muscle tissues.
Downregulated expression of macrophage marker F4/80 dose-dependently.
Inhibited expression of NLRP3 inflammasome components (NLRP3, ASC, pro-caspase-1, cleaved caspase-1, pro-IL-1β, mature IL-1β, HMGB1, Cathepsin B) dose-dependently.
Reduced levels of caspase-11 pathway proteins (pro-caspase-11, cleaved caspase-11, GSDMD, GSDMD-N) dose-dependently.
Suppressed sodium urate-induced expression of NETosis-associated proteins (Cathepsin G, CitH3, PAD4, PR3, NE) dose-dependently.
Reduced SYTOX Green-labeled extracellular DNA release.
Downregulated sodium urate-induced expression of cartilage-degrading enzymes MMP-3 and MMP-13 dose-dependently.
Restored paw glycosaminoglycan content (toluidine blue staining intensity).
Reduced cartilage erosion.

Animal Model:

Kunming mice (male, 6-8 weeks old, acute gout induced by sodium urate crystal subcutaneous air pouch injection)^[1]
Dosage:

25-100 mg/kg
Administration:

i.g.; single dose 1 hour pre-challenge
Result:

Reduced inflammatory cell infiltration in air pouch subcutaneous tissue dose-dependently.
Inhibited NLRP3 inflammasome activation (downregulated HMGB1, Cathepsin B, NLRP3, ASC, pro-caspase-1, cleaved caspase-1, pro-IL-1β, mature IL-1β) dose-dependently.
Suppressed caspase-11-GSDMD pathway activity (downregulated pro-caspase-11, cleaved caspase-11, GSDMD, GSDMD-N) dose-dependently.
Reduced IL-1β levels in air pouch lavage fluid from ~1800 pg/mL (model group) to near-normal levels (~300 pg/mL) at 100 mg/kg.
Inhibited sodium urate-induced NETosis dose-dependently, reducing expression of Cathepsin G, CitH3, PAD4, PR3, and NE.
Decreased co-localization of MPO and SYTOX Green signals.

Animal Model:

C57/BL (male)^[2]
Dosage:

1 mg/kg; 5 mg/kg; 25 mg/kg
Administration:

i.p.; daily; days 14-28
Result:

Reduced alveolar wall thickening and extracellular matrix deposition .
Dose-dependently reduced mortality, partially reversed bleomycin-induced weight loss, and lowered lung hydroxyproline content relative to untreated fibrotic mice.
Decreased bleomycin-induced upregulation of Collagen I and α-SMA mRNA and protein levels.
Activated AMPK phosphorylation in lung tissue, increased autophagic activity, and promoted myofibroblast sensitivity to FasL-induced apoptosis by reducing PTPN13 protein abundance.
Completely reversed antifibrotic, survival-improving, autophagy-activating, and apoptosis-sensitizing effects when co-administered with AMPK inhibitor Compound C .

化学情報

CAS 番号 118555-82-1
性状 Solid
分子量 330.29
分子式 C₁₄H₁₈O₉
Color White to off-white
SMILES

O=C(O)CC1=CC(O)=CC=C1O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O
Structure Classification
- Phenols
- Monophenols
Initial Source
- Plants
- other families
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (302.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0276 mL

15.1382 mL

30.2764 mL

5 mM

0.6055 mL

3.0276 mL

6.0553 mL

10 mM

0.3028 mL

1.5138 mL

3.0276 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (286 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Jiang YJ, et al. Phaseoloidin, a homogentisic acid glucoside from Entada phaseoloides, suppresses gout inflammation via NLRP3 inflammasome. Phytomedicine. 2026;152:157848. [Content Brief]

[2]. Li S, et al. Reversal of Myofibroblast Apoptosis Resistance and Collagen Deposition by Phaseoloidin-Induced Autophagy Attenuates Pulmonary Fibrosis. Biomedicines. 2025;13(11):2679. Published 2025 Oct 31. [Content Brief]

[3]. Weinhold A, et al. Phaseoloidin, a homogentisic acid glucoside from Nicotiana attenuata trichomes, contributes to the plant's resistance against lepidopteran herbivores. J Chem Ecol. 2011;37(10):1091-1098. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.0276 mL	15.1382 mL	30.2764 mL	75.6911 mL
	5 mM	0.6055 mL	3.0276 mL	6.0553 mL	15.1382 mL
	10 mM	0.3028 mL	1.5138 mL	3.0276 mL	7.5691 mL
	15 mM	0.2018 mL	1.0092 mL	2.0184 mL	5.0461 mL
	20 mM	0.1514 mL	0.7569 mL	1.5138 mL	3.7846 mL
	25 mM	0.1211 mL	0.6055 mL	1.2111 mL	3.0276 mL
	30 mM	0.1009 mL	0.5046 mL	1.0092 mL	2.5230 mL
	40 mM	0.0757 mL	0.3785 mL	0.7569 mL	1.8923 mL
	50 mM	0.0606 mL	0.3028 mL	0.6055 mL	1.5138 mL
	60 mM	0.0505 mL	0.2523 mL	0.5046 mL	1.2615 mL
	80 mM	0.0378 mL	0.1892 mL	0.3785 mL	0.9461 mL
	100 mM	0.0303 mL	0.1514 mL	0.3028 mL	0.7569 mL

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Phaseoloidin

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Phenols Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Pulmonary Fibrosis Compound Library

Coagulation and Anti-coagulation Compound Library

Pain-Related Compound Library

Protease Inhibitor Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cell Death Library

Anti-Drug-Resistant Compound Library

Inflammasomes related Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Pattern Recognition Receptors Library

Mongolian Medicine Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

NOD-like Receptor (NLR) アイソフォーム固有の製品をすべて表示

Caspase アイソフォーム固有の製品をすべて表示

AMPK アイソフォーム固有の製品をすべて表示

mTOR アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Phaseoloidin 関連分類

HY-N7400 関連分類